Saskia K. Klein

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Philippe Moreau, Michel Attal, Cyrille Hulin et al. · The Lancet · 2019 · 922 citations · Full text

Hematological Malignancy, Radiation Oncology, Medicine +9

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Shaji Kumar, J H Lee, Juan José Lahuerta et al. · Leukemia · 2011 · 718 citations · Full text

Hematological Malignancy, Medicine, Hematology +9

Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab

Inger S. Nijhof, Richard W.J. Groen, H M Lokhorst et al. · Leukemia · 2015 · 261 citations · Full text

Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients

Gerwin Huls, Dana Chiţu, Violaine Havelange et al. · Blood · 2019 · 172 citations · Full text

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

Philippe Moreau, Cyrille Hulin, Aurore Perrot et al. · The Lancet Oncology · 2021 · 167 citations · Full text

Hematological Malignancy, Medicine, Autologous Stem-cell Transplant +6